

DAFTAR PUSTAKA

1. *Basic TB Facts / TB / CDC.* (n.d.).
<Https://Www.Cdc.Gov/Tb/Topic/Basics/Default.Htm>. Retrieved November 10, 2020, from <https://www.cdc.gov/tb/topic/basics/default.htm>
2. HIV and Tuberculosis (TB). (n.d.-b).
<Https://Hivinfo.Nih.Gov/>. Retrieved November 10, 2020, from <https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-tuberculosis-tb#:%7E:text=Infection%20with%20both%20HIV%20and,considered%20an%20AIDS%2Ddefining%20condition>
3. World Health Organization. (2017, November 13). *Tuberculosis and HIV*. https://www.who.int/hiv/topics/tb/about_tb/en/
4. Straetemans M, Glaziou P, Bierrenbach AL, Sismanidis C, van der Werf MJ (2011) Assessing Tuberculosis Case Fatality Ratio: A Meta-Analysis. *PLoS One*.6(6): e20755
5. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. *AIDS* 22: 1897–1908
6. Torok, M. E., Yen, N. T. B., Chau, T. T. H., Mai, N. T. H., Phu, N. H., Mai, P. P., Dung, N. T., Chau, N. V. V., Bang, N. D., Tien, N. A., Minh, N. H., Hien, N. Q., Thai, P. V. K., Dong, D. T., Anh, D. T. T., Thoa, N. T. C., Hai, N. N., Lan, N. N., Lan, N. T. N., ... Farrar, J. J. (2011). Timing of Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus (HIV)-Associated Tuberculous Meningitis. *Clinical Infectious Diseases*, 52(11), 1374–1383. <https://doi.org/10.1093/cid/cir230>
7. Shao, H. J., Crump, J. A., Ramadhani, H. O., Uiso, L. O., Ole-Nguyaine, S., Moon, A. M., Kiwera, R. A., Woods, C. W., Shao, J. F., Bartlett, J. A., & Thielman, N. M. (2009). Early versus Delayed Fixed Dose Combination Abacavir/Lamivudine/Zidovudine in Patients with HIV and Tuberculosis in Tanzania. *AIDS Research and Human Retroviruses*, 25(12), 1277–1285. <https://doi.org/10.1089/aid.2009.0100>
8. Lanzafame, M., & Vento, S. (2016). Tuberculosis-immune reconstitution inflammatory syndrome. *Journal of Clinical Tuberculosis and Other*

9. D. Laureillard, O. Marcy, Y. Madec, S. Chea, S. Chan, L. Borand, M. Fernandez, N. Prak, C. Kim, B. Dim, Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial, *AIDS* 27 (2013) 2577–2586.
10. French, M. A., Price, P., & Stone, S. F. (2004). Immune restoration disease after antiretroviral therapy. *AIDS*, 18(12), 1615–1627.
<https://doi.org/10.1097/01.aids.0000131375.21070.06>
11. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. *Ann Intern Med* 2012; 157: 313–24.
12. Viskovic, K., & Begovac, J. (2013). Tuberculosis-Associated Immune Reconstruction Inflammatory Syndrome (TB-IRIS) in HIV-Infected Patients: Report of Two Cases and the Literature Overview. *Case Reports in Infectious Diseases*, 2013, 1–7. <https://doi.org/10.1155/2013/323208>
13. Abdool Karim, S. S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A. L., Gengiah, T., Gengiah, S., Naidoo, A., Jithoo, N., Nair, G., El-Sadr, W. M., Friedland, G., & Abdool Karim, Q. (2011). Integration of Antiretroviral Therapy with Tuberculosis Treatment. *New England Journal of Medicine*, 365(16), 1492–1501. <https://doi.org/10.1056/nejmoa1014181>
14. Amogne, W., Aderaye, G., Habtewold, A., Yimer, G., Makonnen, E., Worku, A., Sonnerborg, A., Aklillu, E., & Lindquist, L. (2015). Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/ μ L: TB-HAART Study, a Randomized Clinical Trial. *PLOS ONE*, 10(5), e0122587.
<https://doi.org/10.1371/journal.pone.0122587>
15. Blanc, F.-X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Madec, Y., Marcy, O., Chan, S., Prak, N., Kim, C., Lak, K. K., Hak, C., Dim, B., Sin, C. I., Sun, S., Guillard, B., Sar, B., Vong, S., ...

- Goldfeld, A. E. (2011). Earlier versus Later Start of Antiretroviral Therapy in HIV-Infected Adults with Tuberculosis. *New England Journal of Medicine*, 365(16), 1471–1481. <https://doi.org/10.1056/nejmoa1013911>
16. Havlir, D. V., Kendall, M. A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S. S., Luetkemeyer, A. F., Hogg, E., Rooney, J. F., Wu, X., Hosseinipour, M. C., Laloo, U., Veloso, V. G., Some, F. F., Kumarasamy, N., Padayatchi, N., Santos, B. R., Reid, S., Hakim, J., ... Sanne, I. (2011). Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis. *New England Journal of Medicine*, 365(16), 1482–1491. <https://doi.org/10.1056/nejmoa1013607>
17. Luetkemeyer, A. F., Kendall, M. A., Nyirenda, M., Wu, X., Ive, P., Benson, C. A., Andersen, J. W., Swindells, S., Sanne, I. M., Havlir, D. V., & Kumwenda, J. (2014). Tuberculosis Immune Reconstitution Inflammatory Syndrome in A5221 STRIDE. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 65(4), 423–428. <https://doi.org/10.1097/qai.0000000000000030>
18. Laureillard, D., Marcy, O., Madec, Y., Chea, S., Chan, S., Borand, L., Fernandez, M., Prak, N., Kim, C., Dim, B., Nerrienet, E., Sok, T., Delfraissy, J.-F., Goldfeld, A. E., & Blanc, F.-X. (2013). Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial. *AIDS*, 27(16), 2577–2586. <https://doi.org/10.1097/01.aids.0000432456.14099.c7>
19. Manosuthi, W., Mankatitham, W., Lueangniyomkul, A., Thongyen, S., Likanonsakul, S., Suwanvattana, P., Thawornwan, U., Suntisuklappon, B., Nilkamhang, S., & Sungkanuparph, S. (2012). Time to Initiate Antiretroviral Therapy Between 4 Weeks and 12 Weeks of Tuberculosis Treatment in HIV-Infected Patients. *JAIDS Journal of Acquired Immune Deficiency Syndromes*, 60(4), 377–383. <https://doi.org/10.1097/qai.0b013e31825b5e06>
20. Mfinanga, S. G., Kirenga, B. J., Chanda, D. M., Mutayoba, B., Mthiyane, T., Yimer, G., Ezechi, O., Connolly, C., Kapotwe, V., Muwonge, C.,

- Massaga, J., Sinkala, E., Kohi, W., Lyantumba, L., Nyakoojo, G., Luwaga, H., Doulla, B., Mzyece, J., Kapata, N., ... Onyebujoh, P. (2014). Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial. *The Lancet Infectious Diseases*, 14(7), 563–571.
[https://doi.org/10.1016/s1473-3099\(14\)70733-9](https://doi.org/10.1016/s1473-3099(14)70733-9)
21. Sinha, S., Shekhar, R. C., Singh, G., Shah, N., Ahmad, H., Kumar, N., Sharma, S. K., Samantaray, J. C., Ranjan, S., Ekka, M., Sreenivas, V., & Mitsuyasu, R. T. (2012). Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. *BMC Infectious Diseases*, 12(1), 1–9.
<https://doi.org/10.1186/1471-2334-12-168>
22. Meintjes, G., Rangaka, M. X., Maartens, G., Rebe, K., Morroni, C., Pepper, D. J., Wilkinson, K. A., & Wilkinson, R. J. (2009). Novel Relationship between Tuberculosis Immune Reconstitution Inflammatory Syndrome and Antitubercular Drug Resistance. *Clinical Infectious Diseases*, 48(5), 667–676. <https://doi.org/10.1086/596764>
23. World Health Organization, Global Tuberculosis Report 2016, (2016)
http://www.who.int/tb/publications/global_report/en/ Accessed 19 September 2020.
24. Piscitelli, S. C., & Gallicano, K. D. (2001). Interactions among Drugs for HIV and Opportunistic Infections. *New England Journal of Medicine*, 344(13), 984–996.
<https://doi.org/10.1056/nejm200103293441307>
25. Fishman, J. E., Saraf-Lavi, E., Narita, M., Hollender, E. S., Ramsinghani, R., & Ashkin, D. (2000). Pulmonary Tuberculosis in AIDS Patients. *American Journal of Roentgenology*, 174(1), 43–49.
<https://doi.org/10.2214/ajr.174.1.1740043>
26. Chien, J. W., & Johnson, J. L. (1998). Paradoxical Reactions in HIV and Pulmonary TB. *Chest*, 114(3), 933–936.
<https://doi.org/10.1378/chest.114.3.933>

27. Girardi, E., Palmieri, F., Cingolani, A., Ammassari, A., Petrosillo, N., Gillini, L., Zinzi, D., De Luca, A., Antinori, A., & Ippolito, G. (2001). Changing Clinical Presentation and Survival in HIV-Associated Tuberculosis After Highly Active Antiretroviral Therapy. *Journal of Acquired Immune Deficiency Syndromes*, 26(4), 326–331. <https://doi.org/10.1097/00042560-200104010-00006>
28. Karim, S. S. A., Karim, Q. A., Friedland, G., Laloo, U., & El Sadr, W. M. (2004). Implementing antiretroviral therapy in resource-constrained settings. *AIDS*, 18(7), 975–979. <https://doi.org/10.1097/00002030-200404300-00004>
29. Chelkeba, L., Fekadu, G., Tesfaye, G., Belayneh, F., Melaku, T., & Mekonnen, Z. (2020). Effects of time of initiation of antiretroviral therapy in the treatment of patients with HIV/TB co-infection: A systemic review and meta-analysis. *Annals of Medicine and Surgery*, 55, 148–158. <https://doi.org/10.1016/j.amsu.2020.05.004>
30. Friedland, G. (2009). Tuberculosis Immune Reconstitution Inflammatory Syndrome: Drug Resistance and the Critical Need for Better Diagnostics. *Clinical Infectious Diseases*, 48(5), 677–679. <https://doi.org/10.1086/596765>

Lampiran I. Biodata Penulis

CURRICULUM VITAE

Nama : Nurul Izzah Binti Arifin
Nama Panggilan : Izzah
Tempat, Tanggal Lahir : Kuala Lumpur, 3 Desember 1998
Jenis Kelamin : Perempuan
Agama : Islam
Alamat : Rusunawa UNHAS 1
No. Telpon : 087841633929
Email : nurulizzaharifin020@gmail.com
Motto : “ *Time will heal*”



Riwayat Pendidikan

- a. SD : Sek Keb Danau Kota & SRA Sungai Mulia
- b. SMP & SMA : SMK Danau Kota & SMK Tun Mamat
- c. Foundation : Centre of Foundation Studies, UiTM
- d. Universitas : Fakultas Kedokteran Universitas Hasanuddin

Riwayat Organisasi

- 2018-2019** EXCO Akademik Persatuan Kebangsaan Pelajar Malaysia di Indonesia (PKPMI)
- 2019-2020** EXCO Acara dan Protokol Persatuan Kebangsaan Pelajar Malaysia di Indonesia (PKPMI)

Riwayat Kepanitiaan

1. Divisi Dana dan Usaha Mapres KEMA FK Unhas 2018.
2. *Team Work* Informasi Untuk Mahasiswa (INFUS) Badan Eksekutif Mahasiswa Keluarga Mahasiswa FK Unhas 2019 – 2020.

Riwayat Pelatihan

1. Basic Student Leadership Training (BEM FK Unhas) 2017.